- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06234813
Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study (GLAT)
Glanzmann thrombasthenia is a rare genetic disorder caused by the absence or the dysfunction of the main receptor present on the surface of platelets, integrin αIIbβ3 or GPIIb-IIIa.
The lack of this protein on the surface of platelets no longer allows these blood cells to bind to each other. This binding corresponds to the process of platelet aggregation.
Generally, local measures will control nasal and superficial bleeding whereas platelet transfusions are used to control or prevent life-threatening.
The main complication of this treatment is the risk of developing anti-αIIbβ3 antibodies directed against the absent protein and platelet transfusion therapy can become ineffective.
Activated recombinant factor VII (rFVIIa) provides an alternative treatment for GT patients who develop such antibodies. However, this therapy has a short duration of efficacy, requiring repeated intravenous administrations every 2 to 3 hours.
There is a new treatment, Concizumab, which has not yet been marketed. This treatment acts on TFPI (tissue factor pathway inhibitor). TFPI is a protein that occurs naturally in the body and prevents blood cells from binding to each other.
Concizumab works by blocking TFPI, which may allow sufficient clotting to prevent bleeding.
This treatment could replace recombinant activated factor VII (rFVIIa) because it has the advantage of a much longer duration of efficacy (about 3 days) and is administered subcutaneously.
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen
- Other: : PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM
- Other: Thrombin Generation Assay (TGA) in PRP using TF trigger
- Other: Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis
- Other: Concizumab
Detailed Description
This is in vitro research. The treatment will be tested on blood samples. This will allow us to evaluate in vitro the ability of Concizumab to restore coagulation compared to the usual treatments of platelet transfusions and recombinant activated factor VII (rFVIIa).
This is a single-center study conducted at the Bordeaux University Hospital, which included 10 with Glanzmann thrombasthenia patients and 10 healthy donors over a period of 12 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France
- CHU Bordeaux - Laboratoire Hématologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Glanzmann Thrombasthenia Group:
- Patient ≥18 years old
- Patient with a clear diagnosis of Glanzmann Thrombasthenia (GT), whatever the subtype of disease
- Affiliated person or beneficiary of a social security scheme.
- Free, informed and written consent signed by the participant, and the investigator (at the latest on the day of inclusion and before any examination required by the research)
Control Group:
- Healthy donor ≥ 18 years old
- Healthy donor, without haemorrhagic ant thrombotic medical history
- Person should not work in the investigator's department.
- Affiliated person or beneficiary of a social security scheme
- Free, informed and written consent signed by the participant, and the investigator (at the latest on the day of inclusion and before any examination required by the research)
Exclusion Criteria:
For both patient groups:
- Patient who has taken aspirin or a nonsteroidal anti-inflammatory medication within the previous 10 days
- Patient who has received a platelet transfusion or recombinant activated factor VII hemostatic treatment within the previous 7 days
- Patient who participated in another interventional study involving a drug within 30 days of entering this protocol
- Psychiatric, social or behavioral condition judged to be non-compatible with the respect of the protocol
- Adult protected by the law
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glanzmann Thrombasthenia Group
Patient with a clear diagnosis of Glanzmann Thrombasthenia, whatever the subtype of disease
|
TTAS (single measurements) Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)
ROTEM (single measurements)
TGA (single measurements)
Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA).
Around 1 mL of PRP in total Lysis time in min
Thrombin generation assay (TGA), microchip flow-chamber assay (T-TAS, rotational thromboelastometry and global fibrinolytic capacity to investigate and compare the effects of mixing concizumab (200, 1000 and 4000 ng/mL) with the main bleed treatment options for persons with GT
|
Active Comparator: Healthy donors
Healthy donor without haemorrhagic ant thrombotic medical history
|
TTAS (single measurements) Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)
ROTEM (single measurements)
TGA (single measurements)
Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA).
Around 1 mL of PRP in total Lysis time in min
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of mixing concizumab compared with the main bleed treatment options for persons with GT
Time Frame: One point at the inclusion
|
The samples will be analysed by measurement of in vitro hemostatic capacity :
|
One point at the inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mathieu FIORE, University Hospital, Bordeaux
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Blood Coagulation Disorders, Inherited
- Hemorrhagic Disorders
- Genetic Diseases, Inborn
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Thrombasthenia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Hemostatics
- Coagulants
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Thrombin
- Clotrimazole
- Miconazole
- Thromboplastin
Other Study ID Numbers
- CHUBX 2021/44
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glanzmann Thrombasthenia
-
UMC UtrechtNot yet recruitingGlanzmann Thrombasthenia
-
Rockefeller UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingGlanzmann ThrombastheniaUnited States
-
HaemnetHemab ApSCompletedGlanzmann ThrombastheniaUnited Kingdom
-
University Hospital, BordeauxCompleted
-
Hemab ApSRecruitingGlanzmann ThrombastheniaUnited States, Belgium, France, Italy, Netherlands, United Kingdom
-
AryoGen Pharmed Co.CompletedFactor VII Deficiency | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Glanzmann's ThrombastheniaIran, Islamic Republic of
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Glanzmann's DiseaseJapan
-
University Hospital, LilleRecruitingVideomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases (VIDEO-BLEED)Glanzmann Thrombasthenia | Von Willebrand DiseasesFrance
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Glanzmann's DiseaseSpain, Bulgaria, Pakistan, Belgium, Germany, France, United Kingdom, Italy, Hungary, Netherlands, United States, Algeria, Austria, Sweden, Switzerland
-
Catalyst BiosciencesTerminatedFactor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann ThrombastheniaUnited States, India, Italy, Russian Federation, Ukraine